がん薬物療法の適正化推進に向けた臨床薬学的研究

DOI Web Site Web Site PubMed 被引用文献1件 参考文献24件 オープンアクセス

書誌事項

タイトル別名
  • Clinical Pharmacology Research for Promoting Individualized Cancer Chemotherapy
  • Symposium Review がん薬物療法の適正化推進に向けた臨床薬学的研究
  • Symposium Review ガン ヤクブツ リョウホウ ノ テキセイカ スイシン ニ ムケタ リンショウ ヤクガクテキ ケンキュウ

この論文をさがす

説明

<p>Cancer chemotherapy has progressed remarkably with conventional and molecular-targeted anticancer drugs as well as immune checkpoint inhibitors. However, adverse drug reaction (ADR) management remains a challenge in cancer chemotherapy. Therefore, improving the quality of medical care through clinical pharmacology research is warranted. Intravenous injection of bendamustine in patients with follicular or mantle cell lymphoma frequently causes venous irritation. Because the underlying mechanisms are not clear, we investigated the factors responsible for bendamustine-induced venous irritation. Based on the results of our analysis, we altered the administration regimen and observed that the incidence of venous irritation, which manifested in a concentration-dependent manner following conventional approaches, significantly decreased when following the modified regimen. Guidelines on the management of chemotherapy-induced nausea and vomiting recommend aprepitant, a selective neurokinin-1 (NK-1) receptor antagonist, 5-hydroxytryptamine 3 (5-HT3) receptor antagonists, and dexamethasone as prophylactic antiemetics. Pretreatment with high-dose chemotherapy before hematopoietic stem cell transplantation has extremely high emetogenic potential. This can be countered by using aprepitant in combination with conventional antiemetics. However, the safety and efficacy of such combinations are unexplored. Upon evaluation, we observed improved antiemetic effects without an increase in ADRs. At this symposium, I highlight the significance of clinical pharmacology research for promoting individualized cancer chemotherapy.</p>

収録刊行物

  • 薬学雑誌

    薬学雑誌 139 (6), 901-909, 2019-06-01

    公益社団法人 日本薬学会

被引用文献 (1)*注記

もっと見る

参考文献 (24)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ